FIELD: medicine; pharmaceutics.
SUBSTANCE: disclosed is a method for reducing the risk of MACE in human subjects having type 2 diabetes and a high risk of cardiovascular diseases, where MACE is selected from death due to cardiovascular pathology, non-fatal myocardial infarction, non-fatal stroke and revascularization. Method comprises administering a pharmaceutical composition containing Semaglutide in a therapeutically effective amount, once a week to a subject in need thereof, wherein said subject does not have NYHA class II, III or IV heart failure. MACE is reduced by at least 10 % compared to placebo.
EFFECT: reducing the risk of a serious adverse cardiovascular event (MACE) in human subjects having type 2 diabetes and a high risk of cardiovascular diseases.
18 cl, 2 dwg, 6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| LYRAGLUTIDE FOR CARDIOVASCULAR DISEASE | 2017 |
|
RU2745604C2 |
| COMPOSITIONS AND METHODS FOR REDUCING SERIOUS ADVERSE CARDIOVASCULAR EVENTS | 2014 |
|
RU2711638C2 |
| RENIN-ANGIOTENSIN SYSTEM INHIBITORS APPLICATION FOR PREVENTING CARDIOVASCULAR DISEASE MANIFESTATIONS | 2000 |
|
RU2276997C2 |
| USING PCSK9 INHIBITOR FOR REDUCING CARDIOVASCULAR RISK | 2019 |
|
RU2837845C2 |
| METHODS OF TREATING PATIENTS WITH A HIGH RISK OF CARDIOVASCULAR DISEASES HAVING HYPERCHOLESTEROLEMIA | 2015 |
|
RU2723018C2 |
| METHOD OF TREATING OR PREVENTING ATHEROTHROMBOTIC EVENTS IN PATIENTS WITH MYOCARDIAL INFARCTION IN PAST HISTORY | 2016 |
|
RU2707959C2 |
| GENETIC MARKERS FOR PREDICTING RESPONSE TO THERAPY BY RAISING HDL LEVEL OR IMITATING HDL AGENTS | 2015 |
|
RU2703192C2 |
| GENETIC MARKERS FOR PREDICTION OF SUSCEPTIBILITY TO THERAPY | 2014 |
|
RU2707533C2 |
| TREATMENT OF MYOCARDIAL INFARCTION WITH REGENERATED HIGH-DENSITY LIPOPROTEIN | 2017 |
|
RU2798830C2 |
| METHODS OF TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) | 2015 |
|
RU2735521C2 |
